Skip to main content

Table 1 Patient’s characteristics and baseline tumor features

From: Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen

  Standard CRT Extended CRT p
N 99 12  
Gender (M-F) 47 – 52 (47.5 – 52.5) 7 – 5 (58.3 – 41.7) 0.48
Age (years) 60.3 ± 12.7 58.6 ± 8.4 0.53
Tumor size (mm) 43.2 ± 11.6 43.3 ± 6.5 0.96
Distance anal verge (cm) 3.9 ± 2.0 4.6 ± 1.3 0.13
Initial Staging   
cT 2 6 (6.1 %) 5 (41.7 %)  
  3 87 (87.9 %) 7 (58.3 %)  
  4 6 (6.1 %) 0 (0.0 %) 0.001
cN positive 43 (43.4 %) 8 (66.7 %) 0.11
cUICC I 6 (6.1 %) 3 (25.0 %)  
  II 50 (50.5 %) 1 (8.3 %)  
  III 43 (43.4 %) 8 (66.7 %) 0.006
TRG 3 or 4 22 (30.1 %) 3 (75.0 %) 0.09
CR (cCR or pCR) 23 (23.2 %) 8 (66.7 %) 0.004
Final tumor size (mm) 40.6 ± 22.2 26.4 ± 7.9 0.01
Final Staging    
UICC CCR 16 (16.1 %) 7 (58.4 %)  
  pCR 7 (7.1 %) 1 (8.3 %)  
  I 14 (14.1 %) 1 (8.3 %)  
  II 30 (30.3 %) 0 (0.0 %)  
  III 19 (19.2 %) 2 (16.7 %) 0.004